These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 35690870)

  • 1. Large multicenter randomized trials in autism: key insights gained from the balovaptan clinical development program.
    Jacob S; Anagnostou E; Hollander E; Jou R; McNamara N; Sikich L; Tobe R; Murphy D; McCracken J; Ashford E; Chatham C; Clinch S; Smith J; Sanders K; Murtagh L; Noeldeke J; Veenstra-VanderWeele J
    Mol Autism; 2022 Jun; 13(1):25. PubMed ID: 35690870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of balovaptan for socialisation and communication difficulties in autistic adults in North America and Europe: a phase 3, randomised, placebo-controlled trial.
    Jacob S; Veenstra-VanderWeele J; Murphy D; McCracken J; Smith J; Sanders K; Meyenberg C; Wiese T; Deol-Bhullar G; Wandel C; Ashford E; Anagnostou E
    Lancet Psychiatry; 2022 Mar; 9(3):199-210. PubMed ID: 35151410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Balovaptan vs Placebo for Social Communication in Childhood Autism Spectrum Disorder: A Randomized Clinical Trial.
    Hollander E; Jacob S; Jou R; McNamara N; Sikich L; Tobe R; Smith J; Sanders K; Squassante L; Murtagh L; Gleissl T; Wandel C; Veenstra-VanderWeele J
    JAMA Psychiatry; 2022 Aug; 79(8):760-769. PubMed ID: 35793101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder.
    Bolognani F; Del Valle Rubido M; Squassante L; Wandel C; Derks M; Murtagh L; Sevigny J; Khwaja O; Umbricht D; Fontoura P
    Sci Transl Med; 2019 May; 11(491):. PubMed ID: 31043521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of placebo response in three large clinical trials of the V1a receptor antagonist balovaptan in autism spectrum disorder.
    Tobe R; Zhu Y; Gleissl T; Rossomanno S; Veenstra-VanderWeele J; Smith J; Hollander E
    Neuropsychopharmacology; 2023 Jul; 48(8):1201-1216. PubMed ID: 37045991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism Spectrum Disorder.
    Schnider P; Bissantz C; Bruns A; Dolente C; Goetschi E; Jakob-Roetne R; Künnecke B; Mueggler T; Muster W; Parrott N; Pinard E; Ratni H; Risterucci C; Rogers-Evans M; von Kienlin M; Grundschober C
    J Med Chem; 2020 Feb; 63(4):1511-1525. PubMed ID: 31951127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Placebo response in pharmacological and dietary supplement trials of autism spectrum disorder (ASD): systematic review and meta-regression analysis.
    Siafis S; Çıray O; Schneider-Thoma J; Bighelli I; Krause M; Rodolico A; Ceraso A; Deste G; Huhn M; Fraguas D; Mavridis D; Charman T; Murphy DG; Parellada M; Arango C; Leucht S
    Mol Autism; 2020 Aug; 11(1):66. PubMed ID: 32847616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effectiveness and adverse effects of D-cycloserine compared with placebo on social and communication skills in individuals with autism spectrum disorder.
    Aye SZ; Ni H; Sein HH; Mon ST; Zheng Q; Wong YKY
    Cochrane Database Syst Rev; 2021 Feb; 2(2):CD013457. PubMed ID: 33583058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FASTER and SCOTT&EVA trainings for adults with high-functioning autism spectrum disorder (ASD): study protocol for a randomized controlled trial.
    Tebartz van Elst L; Fangmeier T; Schaller UM; Hennig O; Kieser M; Koelkebeck K; Kuepper C; Roessner V; Wildgruber D; Dziobek I
    Trials; 2021 Apr; 22(1):261. PubMed ID: 33832537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Behavioural and cognitive behavioural therapy for obsessive compulsive disorder (OCD) in individuals with autism spectrum disorder (ASD).
    Elliott SJ; Marshall D; Morley K; Uphoff E; Kumar M; Meader N
    Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013173. PubMed ID: 34693989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, effectiveness, and economic evaluation of an herbal medicine, Ukgansangajinpibanha granule, in children with autism spectrum disorder: a study protocol for a prospective, multicenter, randomized, double-blinded, placebo-controlled, parallel-group clinical trial.
    Lee SH; Shin S; Kim TH; Kim SM; Do TY; Park S; Lee B; Shin HJ; Lee J; Lee JY; Chang GT
    Trials; 2019 Jul; 20(1):434. PubMed ID: 31307524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Open-Label Assessment of the Effects of Itraconazole and Rifampicin on Balovaptan Pharmacokinetics in Healthy Volunteers.
    Derks MGM; Wandel C; Young A; Bolt SK; Meyenberg C
    Adv Ther; 2020 Nov; 37(11):4720-4729. PubMed ID: 32935287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Communication interventions for autism spectrum disorder in minimally verbal children.
    Brignell A; Chenausky KV; Song H; Zhu J; Suo C; Morgan AT
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012324. PubMed ID: 30395694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of V
    Kimi S; Maiti R; Srinivasan A; Mishra BR; Hota D
    Int J Dev Neurosci; 2024 Feb; 84(1):3-13. PubMed ID: 37641183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of prefrontal transcranial direct current stimulation (tDCS) on theory of mind, emotion regulation and emotional-behavioral functions in children with autism disorder: A randomized, sham-controlled, and parallel-group study.
    Zemestani M; Hoseinpanahi O; Salehinejad MA; Nitsche MA
    Autism Res; 2022 Oct; 15(10):1985-2003. PubMed ID: 36069668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Music therapy for people with autism spectrum disorder.
    Geretsegger M; Elefant C; Mössler KA; Gold C
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD004381. PubMed ID: 24936966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioavailability and pharmacokinetic profile of balovaptan, a selective, brain-penetrant vasopressin 1a receptor antagonist, in healthy volunteers.
    Derks M; Lennon-Chrimes S; Guenther A; Squassante L; Wandel C; Szczesny P; Paehler A; Kletzl H
    Expert Opin Investig Drugs; 2021 Aug; 30(8):893-901. PubMed ID: 34176392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent Updates in Psychopharmacology for the Core and Associated Symptoms of Autism Spectrum Disorder.
    Thom RP; Pereira JA; Sipsock D; McDougle CJ
    Curr Psychiatry Rep; 2021 Oct; 23(12):79. PubMed ID: 34643815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale, design, and methods of the Autism Centers of Excellence (ACE) network Study of Oxytocin in Autism to improve Reciprocal Social Behaviors (SOARS-B).
    Spanos M; Chandrasekhar T; Kim SJ; Hamer RM; King BH; McDougle CJ; Sanders KB; Gregory SG; Kolevzon A; Veenstra-VanderWeele J; Sikich L
    Contemp Clin Trials; 2020 Nov; 98():106103. PubMed ID: 32777383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.